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Abstract
Background: Malaria rapid diagnostic tests (RDTs) have generally been found reliable and cost-effective. In Burkina
Faso, the adherence of prescribers to the negative test result was found to be poor. Moreover, the test accuracy
for malaria-attributable fever (MAF) is not the same as for malaria infection. This paper aims at determining the
costs and benefits of two competing strategies for the management of MAF: presumptive treatment for all or use
of RDTs.
Methods: A cost benefit analysis was carried out using a decision tree, based on data previously obtained,
including a randomized controlled trial (RCT) recruiting 852 febrile patients during the dry season and 1,317 in the
rainy season. Cost and benefit were calculated using both the real adherence found by the RCT and assuming an
ideal adherence of 90% with the negative result. The main parameters were submitted to sensitivity analysis.
Results and discussion: At real adherence, the test-based strategy was dominated. Assuming ideal adherence, at
the value of 525 € for a death averted, the total cost of managing 1,000 febrile children was 1,747 vs. 1,862 € in
the dry season and 1,372 vs. 2,138 in the rainy season for the presumptive vs. the test-based strategy. For adults it
was 2,728 vs. 1,983 and 2,604 vs. 2,225, respectively. At the subsidized policy adopted locally, assuming ideal
adherence, the RDT would be the winning strategy for adults in both seasons and for children in the dry season.
At sensitivity analysis, the factors most influencing the choice of the better strategy were the value assigned to a
death averted and the proportion of potentially severe NMFI treated with antibiotics in patients with false positive
RDT results. The test-based strategy appears advantageous for adults if a satisfactory adherence could be achieved.
For children the presumptive strategy remains the best choice for a wide range of scenarios.
Conclusions: For RDTs to be preferred, a positive result should not influence the decision to treat a potentially
severe NMFI with antibiotics. In the rainy season the presumptive strategy always remains the better choice for
children.
Background
Several economic studies have been carried out on
malaria management with rapid diagnostic tests (RDTs)
as a guide to initiate treatment, compared with the pre-
viously common presumptive approach and/or with
microscopy [1-9]. RDTs have generally been found to be
accurate, reliable and cost effective. New WHO guide-
lines on malaria management [10] state that a laboratory
diagnosis of malaria is required for treatment, in all
endemic settings and for all age groups including (con-
trarily to previous guidelines) [11] children under five. A
thorough, multi phase evaluation of several commer-
cially available RDTs is currently underway, and the
results of the first two phases [12,13] show that many of
these tests are highly sensitive down to a very low para-
site density of 200 parasites/μL and also highly specific.
Recently, an estimate of RDT accuracy for malaria-attri-
butable fever rather than for simple infection in rural
Burkina Faso showed that the test under study
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India) had an excellent sensitivity, but a poor specificity
[14]. Moreover, in the same region, the adherence of
prescribers to the negative test result was lower than
20% for both adults and children [15]. An excessive reli-
ance on positive results is not without consequences,
either, as a false positive test may suggest refraining
from treatment with antibiotics: this was indeed the
case of one of the children in the RCT who subse-
quently died, presumably of pneumonia [14].
The aim of this study was to estimate the costs and
benefits of a strategy of presumptive management of
malaria-attributable fever compared to RDT based man-
agement in a rural setting in Burkina Faso. Various sce-
narios were developed incorporating both the observed
(low) adherence to the test results as well as an
“improved” adherence that can be obtained through bet-
ter training and motivation of health personnel. More-
over, in the current algorithm used in the study area,
the positive result is followed by malaria treatment with
no other options, while only the negative result may
lead to a further diagnostic workup for other diseases.
The consequences of not providing antibiotic treatment
to patients who may need it following a false positive
test result were then assessed.
Study design
T h ed a t af o rt h i ss t u d yi sd e r i v e df r o mar a n d o m i z e d
controlled trial carried out in Burkina Faso on the use
of a malaria rapid diagnostic test (RDT) during the dry
season (852 febrile patients) and the rainy season (1,317
febrile patients) [15] and from a previous assessment of
the RDT accuracy for malaria-attributable fever [14].
When primary data was not available or too limited,
assumptions were used based on criteria outlined in the
following sections. The outcome of each strategy is
defined by the following parameters with different values
for adults (Table 1) and children (Table 2): the preva-
lence of malaria-attributable fever in adults and children
in both seasons; the RDT sensitivity and specificity for
malaria-attributable fever in both seasons; the propor-
tion of febrile patients (with and without malaria) trea-
ted with anti-malarials and with antibiotics, in the
presumptive arm and in the RDT arm (according to the
test result), in both seasons; and the excess mortality
(after subtracting the proportion of deaths that would
occur in correctly treated patients) from untreated
malaria as well as from untreated bacterial non malarial
febrile illness (NMFI).
The prevalence of malaria-attributable fever was taken
rather than infection as a proxy of clinical malaria since
it allows for a better classification of cases and related
outcomes. When using data on infection, outcomes
(including death) could be falsely attributed to malaria
instead of NMFI (or vice versa) and thereby lead to
biased conclusions. The specificity of RDTs was not the
same in the two seasons nor in the two age groups,
while sensitivity was related to parasite density. There-
fore, age, season and parasite density-specific data were
used.
Probabilities related to mortality were derived from
the randomized controlled trial [15]. When data was
not or partially available, the following assumptions
were used: for malaria, as the vast majority of patients
in the trial were treated, no death was observed in
untreated patients. Only one death was reported in a
treated child, the latter corresponding to 0.25% case
fatality rate of treated, clinical malaria, or 0.6% if the
denominator is malaria with higher parasite density (>
40,000/μL or >1%). The case fatality rate (CFR) of
untreated malaria with higher parasite density in chil-
dren < 5 years was assumed to be about 10%, based on
expert opinion. For lower parasite densities a lower
CFR was assumed (Table 1). The overall CFR of
untreated malaria (any parasite density) in children
was estimated to be about 2.5%, which is comparable
with previous estimates in other African countries
[1,16,17]. Nevertheless, almost all the untreated
malaria cases were treated with antibiotics, and the
drug used in most cases was cotrimoxazole, which is
still partly effective on malaria in the area. An estimate
was then obtained of malaria CFR in cases not treated
with an anti-malarial, adjusting for the proportion trea-
ted with cotrimoxazole. The CFR for untreated malaria
in RDT negative children was assumed to be much
lower (0.1%), taking into account the lower parasite
density and the favourable outcome of such patients
observed in other studies [18-20] as well as in a pre-
vious study on cases missed by microscopy [21]. For
adults, all the estimates were obviously much lower
(Table 2). As for non-malarial febrile illness (NMFI),
data from the trial showed that the CFR in patients
treated with antibiotics approached 1% both in adults
and children. No death from NMFI was observed in
patients not treated with antibiotics in the presumptive
arm in either age group, and only one in the RDT arm
(a child with a probable pneumonia who was not trea-
ted with antibiotics after a false positive RDT in the
dry season). The only possible explanation of this
apparent paradox is that clinical officers tend to cor-
rectly estimate the potential severity of a febrile illness
and, therefore, treat most of the potentially fatal non-
malarial fevers, while treating a lower proportion of
mild NMFI. Therefore, primary data on antibiotic
treatment of NMFI obtained from the trial were
adjusted to assume a higher proportion of antibiotic
treatment for potentially severe NMFI (assumed to
account for about 20% of all NMFI) and a
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fatality rate of 10% was assumed for untreated cases of
potentially severe NMFI, corresponding to a death rate
of 2% over all untreated NMFI. These assumptions
were based on previous estimates and on expert
opinion and were able to predict the real figures found
by the trial. Figures used for the analysis were those
on excess mortality.
The basis of the model is a decision tree comparing
fever management on a presumptive basis versus
Table 1 Parameters used in the study, children < 5 years
EPIDEMIOLOGICAL PARAMETERS, CHILDREN Source
1
Malaria attributable fevers (MAF)/febrile patients (dry season) 3.18% Primary
Malaria attributable fevers (MAF)/febrile patients (rainy season) 63.05% Primary
Malaria parasite density > 40,000/μL (both seasons) 37.6% Primary
Malaria parasite density ≤40,000/μL (both seasons) 62.4% Primary
Death rate treated MAF, high parasite density 0.60% Primary
Excess death rate untreated MAF, high parasite density 9.4% Assumption
Excess death rate untreated MAF low parasite density 0.25% Assumption
Excess death rate untreated MAF in RDT neg 0.1% Assumption
Death rate treated NMFI 0.84% Primary
Proportion of potentially fatal non malarial fever (PFNM) 20% Assumption
Excess death rate untreated PFNM 7% Assumption
CASE MANAGEMENT, PRESUMPTIVE BRANCH, CHILDREN
Anti-malarial treatment among MAF 94.1% Primary
Anti-malarial treatment among MAF, high parasite density 100% Primary
Anti-malarial treatment among MAF, low parasite density 87% Assumption
Anti-malarial treatment among those treated with antibiotics 86.3% Primary
Anti-malarial treatment among those not treated with antibiotics 97.4% Primary
Antibiotic treatment among NMFI 64.5% Primary
Antibiotic treatment among PFMN 90% Assumption
Antibiotic treatment among patients presumptively treated for malaria 54.4% Primary
Antibiotic treatment among PFMN presumptively treated for malaria 76% Assumption
Antibiotic treatment among patients not presumptively treated for malaria 89.7% Primary
Antibiotic treatment among PFMN not treated for malaria 100% Assumption
CASE MANAGEMENT, RDT, CHILDREN
Anti-malarial treatment among RDT+, high parasite density (hpd) 100% Primary
Anti-malarial treatment among RDT+, low parasite density (lpd) 98.1% Primary
Anti-malarial treatment among RDT- 10.0% Assumption
2
Antibiotic treatment among RDT+ 52.9% Primary
Antibiotic treatment among PFNM RDT+ 76% Assumption
Antibiotic treatment among RDT- 86.1% Assumption
2
Antibiotic treatment among PFNM RDT- 98% Assumption
RDT ACCURACY, CHILDREN
RDT sensitivity, malaria attributable fever (MAF), lpd, dry season 95% Primary
RDT specificity, malaria attributable fever (MAF), dry season 71% Primary
RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season 95.9% Primary
RDT specificity, malaria attributable fever (MAF), rainy season 36.7% Primary
RDT sensitivity, MAF, high parasite density 100% Primary
COSTS, CHILDREN
Cost of RDT 0.71 Ref. 26
Cost of anti-malarial treatment, Coartem (average, €) 1 Ref. 26
Cost of antibiotic treatment (average, €) 0.5 Estimate
Life Value (€) corresponding to 25 US $*YLL 525 (see text)
Life Value (€) corresponding to 150 US $*YLL 3150 (see text)
1 Primary data obtained from previous RCT (Ref. 15) and from previous assessment of the RDT accuracy (Ref. 14); assumptions based on estimates from primary
data, expert opinion and previous literature (see explanation in text).
2 Assuming “ideal” 90% adherence to the negative test result (see explanation in text).
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detection of malaria for a hypothetical cohort of 1,000
patients presenting with axillary temperature ≥ 37.5 °C
at a primary health centre (Figure 1). In this study we
use cost-benefit analysis whereby the cost of each strat-
egy is combined with its outcome expressed in monetary
terms, in this case the value of deaths averted. Using the
same decision tree structure, we estimated the outcome
for four different groups: (i) children in the dry season,
(ii) adults in the dry season, (iii) children in the rainy
season and (iv) adults in the rainy season. Children were
defined as patients below the age of five (<5yrs), and
Table 2 Parameters used in the study, children ≥ 5 years and adults
EPIDEMIOLOGICAL PARAMETERS Source
1
Malaria attributable fevers (MAF)/febrile patients (dry season) 1.7% Primary
Malaria attributable fevers (MAF)/febrile patients (rainy season) 25.1% Primary
Malaria parasite density > 40,000/μL (both seasons) 36.8% Primary
Death rate treated MAF, high parasite density 0.0% Primary
Excess death rate untreated MAF, high parasite density 0.4% Assumption
Excess death rate untreated MAF low parasite density 0.0% Assumption
Excess death rate untreated MAF in RDT neg 0.0% Assumption
Death rate treated NMFI 0.84% Primary
Proportion of potentially fatal non malarial fever (PFNM) 20% Assumption
Excess death rate untreated PFNM 7% Assumption
CASE MANAGEMENT, PRESUMPTIVE BRANCH, ADULTS
Anti-malarial treatment among MAF 97% Primary
Anti-malarial treatment among MAF, high parasite density 97.3% Primary
Anti-malarial treatment among MAF, low parasite density 97% Assumption
Anti-malarial treatment among those treated with antibiotics 79.3% Primary
Anti-malarial treatment among those not treated with antibiotics 94.8% Primary
Antibiotic treatment among NMFI 56.1% Primary
Antibiotic treatment among PFMN 90% Assumption
Antibiotic treatment among patients presumptively treated for malaria 47.1% Primary
Antibiotic treatment among PFMN presumptively treated for malaria 86% Assumption
Antibiotic treatment among patients not presumptively treated for malaria 80.8% Primary
Antibiotic treatment among PFMN not treated for malaria 99% Assumption
CASE MANAGEMENT, RDT, ADULTS
Anti-malarial treatment among RDT+, high parasite density (hpd) 100% Primary
Anti-malarial treatment among RDT+, low parasite density (lpd) 96.4% Primary
Anti-malarial treatment among RDT- 10% Assumption
Antibiotic treatment among RDT+ 42.5% Primary
Antibiotic treatment among PFNM RDT+ 86% Assumption
Antibiotic treatment among RDT- 77.4% Assumption
Antibiotic treatment among PFNM RDT- 98.6% Assumption
RDT ACCURACY, ADULTS
RDT sensitivity, malaria attributable fever (MAF), lpd, dry season 91.6% Primary
RDT specificity, malaria attributable fever (MAF), dry season 78.7% Primary
RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season 95.3% Primary
RDT specificity, malaria attributable fever (MAF), rainy season 77.4% Primary
RDT sensitivity, MAF, high parasite density 99% Primary
COSTS, ADULTS
Cost of RDT 0.71 (ref. 26)
Cost of anti-malarial treatment, Coartem (average, €) 2 (ref. 26)
Cost of antibiotic treatment (average, €) 0.4 Estimate
Life Value (€) corresponding to 25 US $*YLL 525 (see text)
Life Value (€) corresponding to 150 US $*YLL 3150 (see text)
1 Primary data obtained from previous RCT (ref. 15) and from previous assessment of the RDT accuracy (ref. 14); assumptions based on estimates from primary
data, expert opinion and previous literature (see explanation in text)
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For each cohort, two scenarios were modelled that dif-
fered in terms of the clinicians’ adherence to the test
results. First, the analysis was carried out using adher-
ence rates as observed in the RCT [15]. The clinicians’
adherence to the negative RTD result was very poor in
both age groups and in both seasons. Interestingly, the
adherence to the presumptive strategy for malaria treat-
ment was not 100% but about 90% and also the adher-
ence to the positive RDT result, although very high, was
Figure 1 Structure of the Decision Tree.
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treated increased with parasite density in both arms and
approached 100% for parasite densities over 40,000/μL
indicating that, similarly to NMFI (see above), poten-
tially severe cases are more likely to be treated. The pro-
portion of patients treated with antibiotics was also
much higher in patients not treated for malaria, and
vice versa (Tables 1 and 2). A further analysis was per-
formed assuming that through better training, motiva-
tion and supervision it would be possible to
substantially increase the adherence to the negative test
result, consistently with findings from other studies:
[18,22,23] an ideal value of 90% was assumed, compared
to less than 20% observed in the field. The adherence to
the positive test was assumed to be 100%, while the
adherence rates of the presumptive management of feb-
rile patients were not varied.
The cost benefit approach implies that a monetary
value be assigned to the main health outcome, that is, a
death averted by correct case management by either
strategy. We started the analysis with the very low value
of 525 € (euro) for a death averted, which roughly corre-
sponds to 25 US $ for a YLL avoided (that is a sug-
gested benchmark for a “highly attractive” health
intervention) [1]. The upper range in the tree was 3,150
€ (euro), which roughly corresponds to 150 US $ for a
YLL, a benchmark for an attractive intervention [1]. For
the estimate of years of life lost (YLL) we used the equa-
tion described by Fox-Rushby and Hanson [24]. In Bur-
kina Faso, according to the most recent estimates [25],
the life expectancy at birth was 52.9 years. The median
age of the study cohort was one year for children and
18 years, for adults. A death at this age would corre-
spond to YLLs[0.03,1,0.04] = 30.8 for a child and = 30.4
for an adult. For convenience, both were set at 30.
Costs were considered from a societal perspective and
included the cost of the rapid diagnostic test, malaria
drug treatment cost and the cost of antibiotic treatment
for children and adults. Prices for both the anti-malar-
ials (artemisinin-based combination therapy (ACT);
Coartem
®) and the RDT (Paracheck Device
®,O r c h i d
Biomedical Systems, Goa, India) were obtained from a
leading international no-for-profit supplier (2010 price
list) [26]. These costs are currently partly subsidized by
external sources. In the study area, the RDT is currently
fully subsidized and performed at no charge and the
ACT average subsidized cost is 100 CFA (0.15 €)f o r
children under 5 and 250 CFA (0.38 €) for adults (see
Tables 1 and 2). The analysis was first performed con-
sidering all inputs at their full cost and subsequently
using the subsidized costs.
Costs in local currency (CFA franc) were converted to
Euros at a (fixed) exchange rate (100 CFA francs = 1
former French franc = € 0.00152449). The value of YLLs
expressed in US dollars was converted to Euros at US
$1.43/euro (January 21
st, 2010). Analyses were per-
formed using TreeAge Pro Suite v1.0.2 (Treeage Inc,
Williamstown, MA, USA).
Sensitivity analysis
As a previous, similar study [1] showed that results were
most sensitive to the monetary value assigned to YLLs,
the threshold life value (that is the monetary value
assigned to a death averted at which the two strategies
become equivalent) was first calculated for each group/
season, when applicable.
The compliance as well as the other main factors were
also submitted to a sensitivity analysis. The range of var-
iation for primary data was provided by the 95% confi-
dence interval, while that for assumptions was wide
enough to challenge the robustness of the main conclu-
sions. The hypothesis that a false positive RDT result
(for malaria-attributable fever) might influence the man-
agement of NMFI was also tested. For the main analysis
the results of the primary data were used, i.e. the pro-
portion of NMFI with a false positive RDT treated with
antibiotics was the same as among patients presump-
tively treated for malaria. For sensitivity analysis, a
higher proportion of patients was assumed to be treated
only with an anti-malarial without antibiotics in case of
a positive RDT result, if compared with the presumptive
management.
Results
Patient population
The characteristics of the study population are described
in detail elsewhere [14,15]. To summarize, primary data
for this study were obtained from 852 febrile patients in
the dry season and 1,317 in the rainy season. The pro-
portion of children under five (median age: 1 year) and
adults (median age 18 years) was 50.9% and 49,1%
respectively. The main data on malaria and NMFI pre-
valence and on case management are resumed in Table
1 (children) and Table 2 (adults).
Cost benefit at observed versus ideal adherence
At the adherence levels found by the trial, the test-based
strategy was clearly disadvantageous in both seasons and
for both age groups. In particular, total costs of the pre-
sumptive strategy compared to the test-based strategy
for children were 1,747€ vs. 2,615€ in the dry season
and 1,372€ vs. 2,284 € in the rainy season. For adults
total costs were 2,728€ vs. 3,369€ and 2,604€ vs. 3,271€
respectively (Table 3).
Assuming an ideal adherence of 90% by health provi-
ders to the negative test results total costs were 1,747€
vs. 1,862 € in the dry season and 1,372€ vs. 2,138€ in
the rainy season for the presumptive vs. the test based
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2,604€ vs. 2,225€ respectively (Table 4).
Cost benefit at current subsidized costs
When the subsidized costs for anti-malarial drugs and
rapid diagnostic tests are considered (i.e. the financial
cost to the malaria control programme and patients)
rather than the full cost (that includes donor support) at
current adherence levels, the presumptive strategy is still
preferred for children in both seasons while the test
based strategy is the more attractive for adults (Table 5).
At ideal adherence levels, the presumptive strategy is
dominated for adults in both seasons and for children in
the dry season, but still remains the better alternative
for children in the rainy season (Table 6).
Sensitivity analysis
The sensitivity analysis showed that, besides the adher-
ence and the costs of the test and treatment, the results
were influenced by the monetary value assigned to a
death averted and by the potential effect of the RDT
(false) positive result on the treatment of NMFI with
antibiotics.
The effect of the life value on the main results,
“ceteris paribus”, is resumed in Tables 3 to 6 by the
“threshold life value”, that is the monetary value
assigned to a death averted at which the two strategies
are equivalent. At the real adherence level found by the
trial, for children in both seasons the test-based strategy
was dominated for any value assigned to a life saved,
w h i l ef o ra d u l t si nt h ed r ya n di nt h er a i n ys e a s o nt h e
test based strategy would only become advantageous at
a life value > 6,958€ and 9,071 € (Table 3), correspond-
ing to about 232 and 302 € per YLL prevented,
respectively.
At the “ideal” adherence level, for adults in both sea-
sons the presumptive strategy was dominated for any
value assigned. For children, in the dry season, the test-
based strategy became advantageous at a life value of >
1,151€, corresponding to a YLL value of 38 €, while in
the rainy season the test based strategy was dominated
(Table 4). Given the current subsidized costs, the test-
based strategy is the winning option for adults, regard-
less the adherence, while for children the same strategy
becomes advantageous at the ideal adherence level, but
only in the dry season (Tables 5 and 6).
Effect of the proportion of RDT false positive NMFI
treated with antibiotics
Given the ideal adherence values of the main analysis,
assuming that the improved confidence with the test result
would have the effect of decreasing the proportion of anti-
biotic treatment in NMFI with a false positive RDT, we
report the possible effect of this variable for both seasons
and age groups (Figures 2, 3, 4, 5, 6, 7, 8, 9, 10, 11). For
children in the dry season the RDT based strategy would
only become advantageous if the proportion of potentially
fatal NMFI treated with antibiotics among RDT positives
Table 3 Direct cost (test and treatment cost) and comprehensive cost (including estimate of life value) of the
presumptive versus the test based strategy at “real life” adherence levels to both strategies (see text): test and
treatment cost not subsidized
Variables Children, dry season Children, rainy season Adults, dry season Adults, rainy season
Direct cost, presumptive strategy 1032 1033 2005 2048
Direct cost, test-based strategy 1713 1767 2699 2758
Comprehensive cost, presumptive strategy 1747 1372 2728 2604
Comprehensive cost, test-based strategy 2615 2284 3369 3271
Threshold life value* n.a. (test dominated) n.a. (test dominated) 6958 9071
Costs expressed in € (euro) for 1000 patients managed with either strategy, assuming a life value of 525 € (better option in bold)
* Life value at which the two strategies become equivalent at sensitivity analysis
Table 4 Direct cost (test and treatment cost) and comprehensive cost (including estimate of life value) of the
presumptive versus the test based strategy at “ideal” adherence levels to both strategies (see text): test and
treatment cost not subsidized
Variables Children, dry season Children, rainy season Adults, dry season Adults, rainy season
Direct cost, presumptive strategy 1032 1033 2005 2047
Direct cost, test-based strategy 1242 1684 1685 1988
Comprehensive cost, presumptive strategy 1747 1372 2728 2604
Comprehensive cost, test-based strategy 1862 2138 1983 2225
Threshold life value* 1151 n.a. (test dominated) n.a. (pres. dominated) n.a. (pres. dominated)
Costs expressed in € (euro) for 1000 patients managed with either strategy, assuming a life value of 525 € (better option in bold)
* Life value at which the two strategies become equivalent at sensitivity analysis
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analysis including life value (Figure 3), the required pro-
portion of antibiotic treatment would remain over 75%
even for much higher values assigned to life. For children
in the rainy season, the test-based strategy would remain
dominated for any value assigned to both variables. For
adults in both seasons, the RDT based strategy would
remain the preferred one if more than half potentially fatal
NMFI with a positive test result were treated with antibio-
tics (Figures 4 and 5). Even at the current subsidized policy
(see above), the test-based strategy would be no longer
advantageous if the proportion of potentially fatal NMFI
treated with antibiotics among RDT (false) positives
dropped to < 69%, < 50% and < 52% for children in the
dry season and adults in the dry and rainy season, respec-
tively (Figures 6 to 8). The two-way sensitivity analysis
including the life value (Figures 9 to 11) gave very similar
results.
Discussion
General findings
In a hyperendemic malaria region, with a very marked
difference in transmission intensity such as in the study
area, the optimal choice in terms of cost benefit between
the two competitive strategies is not straightforward. At
the adherence level (to the negative test result) found by
the trial in the study area [15], a test-based policy is
clearly disadvantageous for both seasons and age groups,
confirming that the prescribing behaviour is a crucial
operational factor affecting the new policy recom-
mended by the WHO [10].
Assuming that through better training and motivation
care providers become more confident on the negative
test result using an ideal adherence of 90%, the test-
based strategy would become the best option for adults
in both seasons, but not for children. At the ideal adher-
ence and leaving other factors unchanged, a test-based
policy would dominate a presumptive strategy at the
current subsidized pricing policy, with the notable
exception of children in the rainy season.
Besides adherence and cost of the test and treatment,
the sensitivity analysis pointed to the value of life and to
the effect of false positive RDT results on antibiotic pre-
scription as key determinants. Given the “ideal” adher-
ence, at a slightly higher life value the test-based
strategy would become attractive for children, but only
in the dry season. No increase in life value would make
the RDT based strategy attractive for children in the
rainy season, while a decrease in the proportion of
potentially fatal NMFI treated with antibiotics following
af a l s ep o s i t i v eR D Tw o u l dr a d i c a l l yc h a n g et h em a i n
conclusions and make the test based policy the less
attractive also for the other three groups.
Comparison with previous studies
Methodology
This analysis differs from previous studies in two main
methodological aspects. First, the RDT accuracy values
Table 5 Direct cost (test and treatment cost) and comprehensive cost (including estimate of life value) of the
presumptive versus the test based strategy at the current “real life” adherence levels to both strategies: test and
treatment cost subsidized (see text)
Variables Children, dry season Children, rainy season Adults, dry season Adults, rainy season
Direct cost, presumptive strategy 264 257 608 608
Direct cost, test-based strategy 256 255 609 610
Comprehensive cost, presumptive strategy 979 596 1330 1164
Comprehensive cost, test-based strategy 1157 760 1279 1125
Threshold life value* 23 7 14 25
Costs expressed in € (euro) for 1000 patients managed with either strategy, assuming a life value of 525 € (better option in bold)
* Life value at which the two strategies become equivalent at sensitivity analysis
Table 6 Direct cost (test and treatment cost) and comprehensive cost (including estimate of life value) of the
presumptive versus the test based strategy at “ideal” adherence levels to both strategies: test and treatment cost
subsidized (see text)
Variables Children, dry season Children, rainy season Adults, dry season Adults, rainy season
Direct cost, presumptive strategy 264 257 608 608
Direct cost, test-based strategy 209 247 485 516
Comprehensive cost, presumptive strategy 978 596 1330 1164
Comprehensive cost, test-based strategy 828 697 782 752
Threshold life value* n.a. (pres. dominated) 44 n.a. (pres. dominated) n.a. (pres. dominated)
Costs expressed in € (euro) for 1000 patients managed with either strategy, assuming a life value of 525 € (better option in bold)
* Life value at which the two strategies become equivalent at sensitivity analysis
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Page 8 of 13used for the analysis refer to malaria-attributable fever,
and not simply to malaria infection [14]. Though the
accuracy values given are based on estimates, the advan-
tage is a more correct classification of malaria and of
non-malarial febrile illness (NMFI). Secondly, data on
mortality, both for malaria and NMFI, are not simply
derived from general literature data and/or from expert
opinion, but on estimates based on real data found by a
previous trial, and so are all data on case management.
Adherence
The effect of adherence has already been discussed
[1,27]. At a very low adherence level to the negative
result a test based strategy cannot be cost effective: the
test only adds an unnecessary cost, if its result will not
change the decision to treat [27]. Nevertheless, in other
study settings a much better compliance was observed
suggesting that a similar result could be obtained in
Burkina Faso too [18,22,28]. However, the results of this
study indicate that even at an ideal adherence the test
based strategy offers a clear and undisputable advantage
for adults only.
Life value
Similarly to a study carried out with a similar methodol-
ogy the results were most sensitive to the cost assigned
to a year of life lost [1]. In this study the value assigned
to a death averted was crucial to indicate the best
option for some of the scenarios discussed, while for
other the best choice was insensitive to this factor,
obviously difficult to estimate, especially for low and
very low income countries.
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Page 9 of 13Antibiotic prescription
Previous studies suggest that clinicians and nurses tend
to treat fewer patients with antibiotics when a malaria
test is positive which is by no means surprising [9,29].
Nurses active in the study area when asked what the
main advantage of the RDT were answered that “the
positive result is useful as it permits to rule out other
diseases” (Federico Gobbi, personal communication,
November 2010). The results on the effect of antibiotic
prescription after a false positive test are understand-
able, considering that the test specificity for malaria-
attributable fever was particularly low. This is so,
because a proportion of low-density infections that are
detected by the RDT cannot be considered malaria in
clinical terms and are, therefore, classified as false posi-
tive for this study purpose [14].
Weaknesses and limitations
There are also a number of limitations to this study.
Although most of the parameters used for the analysis
are primary data obtained from direct observation or on
best estimates from primary data, some of them are
necessarily based on assumptions and/or expert opinion,
which is common to most health economic studies.
Given the weight of health outcome on the final result,
when very small differences in outcome (deaths averted)
are observed, the results need to be taken with extreme
caution. This study did not consider certain costs such
as material (disposable gloves, lancets) and labour cost
that would have increased the cost of the test-based
strategy. Time cost for patients and guardians and cost
of referral and secondary care are not considered either
because they are difficult to estimate and also because
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Page 10 of 13the previous trial showed that only a very negligible pro-
portion of patients were referred [15]. Last but not least,
this study assumes that only febrile patients are tested.
Other studies found that care providers also tested a
proportion of patients without fever or even without a
recent fever history [19,20]. Should this practice become
the rule, it would further hamper the potential cost sav-
ing of the test-based management.
Possible impact
The previous trial did not show any significant differ-
ence in the proportion of antibiotic treatment between
patients in the presumptive arm and those with a posi-
tive RDT result [15]. If an improved confidence in the
test is obtained through better training and motivation,
in order to achieve a better adherence to the negative
result, it is only too logical to expect a corresponding,
higher reliance on the positive result, as well, which
would affect antibiotic prescription. It can be argued
that the possible disastrous effect of a false positive
RDT result on antibiotic prescription for potentially
severe NMFI is compensated by a higher proportion of
antibiotic prescription to RDT negatives. This is
obviously true, but this effect is already accounted for in
our model, as this proportion is estimated to be close to
100%.
In more general terms, this study shows that a test-
based policy is advantageous only if it leads to improved
medical decisions. The presumptive strategy certainly
causes an over prescription of both anti-malarials and
antibiotics, but the advantage is that most potentially
severe cases are treated. RDTs should limit anti-malarial
prescription through an “ideal” adherence to the nega-
tive test result [18,27]. The adverse consequences of a
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Page 11 of 13false negative RDT are probably negligible [18], though
a word of caution is warranted for young children and
infants [14], until definitive conclusions on safety are
reached [30]. On the other hand, this study suggests
that a positive RDT result should not necessarily
become a reason to refrain from antibiotic treatment.
Clinical guidelines, including the Integrated Manage-
ment of Childhood Ilnesses (IMCI), should introduce
RDTs at the right step. The treatment decision for
NMFI should come before the RDT node in clinical
algorithms, and the RDT result should be used as a
guide for malaria treatment, but not to exclude other
potential causes of fever.
Moreover, even under an “ideal” prescribing beha-
viour, the choice of a test-based strategy remains ques-
tionable for children under five, especially in the rainy
season.
Future research
Randomized controlled trials (RCTs) with adequate
sample size on the outcome of a test-based versus a pre-
sumptive strategy are unfortunately lacking, which
means that the widespread introduction of RDTs and
their adoption as the optimal strategy everywhere and
for all ages are not based on undisputable evidence [10].
If adequately powered RCTs are manageable and worth
the necessary investment remains matter for discussion.
Conclusions
For a test-based strategy to be preferred over a pre-
sumptive strategy in terms of cost and benefit, a near
ideal adherence to the negative test result is needed,
while a positive test result should not influence the deci-
sion to treat a potentially severe NMFI with antibiotics.
Even if such ideal case management could be achieved,
the RDT based strategy should be subsidized in order to
be advantageous for young children in the dry season,
while in the rainy season the presumptive strategy
remains the better choice for children in all scenarios.
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